Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at Bradykinin Symposium 2026

Data ReadoutpositiveBW-20805Positive

AI Analysis

Summary

Argo Biopharma announced positive Phase II updated results for siRNA therapeutic BW-20805 for hereditary angioedema, to be presented at the Bradykinin Symposium 2026.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Positive Phase II updated results

Importance:6/10

Sentiment:

0.70

siRNAPhase 2Hereditary Angioedemaclinical trialdata presentation

Read the original article

Published by PR Newswire Clinical Trials on September 4, 2026 6:00 AM

Read Original